SMT201200029B - Composizione farmaceutica stabile per il rilascio ottimizzato di un inibitore dell'attacco dell'hiv. - Google Patents

Composizione farmaceutica stabile per il rilascio ottimizzato di un inibitore dell'attacco dell'hiv.

Info

Publication number
SMT201200029B
SMT201200029B SM201200029T SM201200029T SMT201200029B SM T201200029 B SMT201200029 B SM T201200029B SM 201200029 T SM201200029 T SM 201200029T SM 201200029 T SM201200029 T SM 201200029T SM T201200029 B SMT201200029 B SM T201200029B
Authority
SM
San Marino
Prior art keywords
pharmaceutical composition
stable pharmaceutical
optimized release
attack inhibitor
hiv
Prior art date
Application number
SM201200029T
Other languages
English (en)
Inventor
Jonathan R Brown
Helen Toale
Andrew B Dennis
Peter Timmins
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of SMT201200029B publication Critical patent/SMT201200029B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM201200029T 2008-09-04 2012-06-19 Composizione farmaceutica stabile per il rilascio ottimizzato di un inibitore dell'attacco dell'hiv. SMT201200029B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9413108P 2008-09-04 2008-09-04
PCT/US2009/055820 WO2010028108A2 (en) 2008-09-04 2009-09-03 Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor

Publications (1)

Publication Number Publication Date
SMT201200029B true SMT201200029B (it) 2012-09-07

Family

ID=41726353

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201200029T SMT201200029B (it) 2008-09-04 2012-06-19 Composizione farmaceutica stabile per il rilascio ottimizzato di un inibitore dell'attacco dell'hiv.

Country Status (16)

Country Link
US (2) US20100056540A1 (it)
EP (1) EP2323633B1 (it)
JP (1) JP5638527B2 (it)
CN (1) CN102143739B (it)
AT (1) ATE550016T1 (it)
CA (1) CA2735008C (it)
CY (1) CY1112816T1 (it)
DK (1) DK2323633T3 (it)
ES (1) ES2383149T3 (it)
HR (1) HRP20120441T1 (it)
NL (1) NL301118I2 (it)
PL (1) PL2323633T3 (it)
PT (1) PT2323633E (it)
SI (1) SI2323633T1 (it)
SM (1) SMT201200029B (it)
WO (1) WO2010028108A2 (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5124327A (en) * 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
JP2686215B2 (ja) * 1993-04-28 1997-12-08 信越化学工業株式会社 徐放性錠剤
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
GT200500375A (es) * 2004-12-20 2006-11-28 Derivados de piperidina y su uso como agentes antiinflamatorios
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents

Also Published As

Publication number Publication date
CY1112816T1 (el) 2016-02-10
SI2323633T1 (sl) 2012-07-31
EP2323633B1 (en) 2012-03-21
ES2383149T3 (es) 2012-06-18
NL301118I1 (it) 2021-07-23
JP2012502042A (ja) 2012-01-26
WO2010028108A3 (en) 2010-09-02
DK2323633T3 (da) 2012-07-09
US20150158891A1 (en) 2015-06-11
NL301118I2 (nl) 2022-02-22
PT2323633E (pt) 2012-05-29
HRP20120441T1 (hr) 2012-06-30
CA2735008A1 (en) 2010-03-11
CN102143739B (zh) 2014-12-17
PL2323633T3 (pl) 2012-08-31
CA2735008C (en) 2016-11-29
JP5638527B2 (ja) 2014-12-10
WO2010028108A2 (en) 2010-03-11
US20100056540A1 (en) 2010-03-04
EP2323633A2 (en) 2011-05-25
ATE550016T1 (de) 2012-04-15
CN102143739A (zh) 2011-08-03

Similar Documents

Publication Publication Date Title
WO2008076862A3 (en) 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors
RS53704B1 (en) NEW PHENILIMIDAZOLA DERIVATIVE KAO INHIBITOR ENZIMA PDE10A
MX2011012198A (es) Aril-piridinas como inhibidoras de sintasa de aldosterona.
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
PE20140960A1 (es) Formulaciones que comprenden un inhibidor de dpp4
MX2020001259A (es) Composiciones farmaceuticas que comprenden un modulador de s1p.
EA200900135A1 (ru) Производные пиразола в качестве ингибиторов цитохрома р450
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
TN2011000207A1 (en) Akt and p70 s6 kinase inhibitors
GB2459393B (en) Novel capsule formulation for the proton pump inhibitor omeprazole
WO2007070589A3 (en) Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
NI200900052A (es) Heterocíclicos derivados de los inhibidores de metaloproteasa
NZ592927A (en) PHOSPHODIESTERASE TYPE III (PDE III) INHIBITORS OR CA2+-SENSITIZING AGENTS such as pimobendan FOR THE TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY
ECSP088957A (es) Composición farmacéutica estable que contiene docetaxel y método para su fabricación
UY32299A (es) Composiciones farmacéuticas líquidas
BR112012007179B8 (pt) composto inibidor da di-hidro-orotato desidrogenase, e, formulação farmacêutica
AR058047A1 (es) Administracion de inhibidores de dipeptidil peptidasa
NL301118I2 (nl) Fostemsavir
WO2008009802A3 (fr) Medicaments comprenant un inhibiteur des alpha-mannosidases de classe i pour le traitement des sarcoglycanopathies
TNSN08531A1 (en) Phenylacetic acid derivatives as cox - 2 inhibitors
CL2007003146A1 (es) Composición farmacéutica que comprende un compuesto derivado de indol y un sistema portador que comprende 15-25% de un mejorador de la viscosidad, 5-15% de un solubilizante, 10-50% de un diluyente y 1-10% de un estabilizante; proceso de preparación; y forma de dosificación.
DK2089030T3 (da) Middel til profylakse eller behandling af alkoholafhængighed eller lægemiddelafhængighed
MX2009013054A (es) Composicion farmaceutica que comprende un sustrato y un revestimiento que contiene un ingrediente activo y alcohol polivinilico.
MX2009003793A (es) Inhibidores de cinasa.